Osteoporose i almen praksis

Rapport om osteoporose i det Europæiske Fællesskab. En forebyggelsesindsats. Europa-Kommisionen, 1999.

Osteoporosis. San Diego, California: Academic Press, 2001.

Assesment of fracture risk and its application to screening for postmenopausal osteoporosis: Reports of a WHO study group, Geneva: WHO Tecnical Report Series 843, 1994. WHO Tecnical Report Series 843, 1994 2001.

The American Society for Bone and Mineral Research: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Philidelphia: Lippinecut Williams & Wilkins, 1999.

Mosekilde L, Beck-Nielsen H, Sorensen OH, Nielsen SP, Charles P, Vestergaard P et al. Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study. Maturitas 2000;36:181-93.

Nguyen T, Sambrook P, Kelly P, Jones G, Lord S, Freund J et al. Prediction of osteoporotic fractures by postural instability and bone density. BMJ 1993;307:1111-5.

Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151:2026-32.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.

Kanis JA, Johnell O, Oden A, Dawson A, de Laet C, Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 2001;12:989-95.

Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.

Larsen E. Falling and fractures among elderly community residents: risk factors and prevention (ph.d.-afhandling, Århus Universitet), 2002.

Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS et al. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int 2001;12:519-28.

Johnell O. Risk factors for osteoporotic fractures. In Genant HK, Gugleilmi G, Jergas M, eds. Bone densitomety and osteoporosis, Berlin: Springer Verlag, 1998.

Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-9.

Hyldstrup L. Klar besked om knogleskørhed- årsager, forebyggelse og behandling. Aschehoug, 1996.

Poulstrup A. Prevention of medically treated injuries from falls in aged living at home. A controlled prospective intervention study. Ph.d.-afhandling. Odense Universitet, 1992.

Mosekilde L. Osteoporosis and exercise. Bone 1995;17:193-5.

EBM Guidelines (CD-ROM). PO Box 713; Helsinki, Finland: Duodecim Medical Productions LTD, 2001.

Drinkwater BL, Nilson K, Chesnut CH, III, Bremner WJ, Shainholtz S, Southworth MB. Bone mineral content of amenorrheic and eumenorrheic athletes. N Engl J Med 1984;311:277-81.

Marcus R, Cann C, Madvig P, Minkoff J, Goddard M, Bayer M et al. Menstrual function and bone mass in elite women distance runners. Endocrine and metabolic features. Ann Intern Med 1985;102:158-63.

Matkovic V. Calcium and peak bone mass. J Intern Med 1992;231:151-60.

Michaelsen KF, Astrup A, Mosekilde L, Richelsen B, Schroll M, Sørensen OH. Ernæringens betydning for forebyggelse af knogleskørhed (En rapport fra Ernæringsrådet), 2000.

Osteoporose. Forebyggelse, diagnostik og behandling (Sundhedsstyrelsen og Fødevaredirektoratet), 2000.

Mosekilde L. Vitamin D, osteomalacia and renal osteodystrophy. 2001.

MacLaughlin J, Holick MF. Aging decreases the capacity of human skin to produce vitamin D3. J Clin Invest 1985;76:1536-8.

Johnell O, Gullberg B, Kanis JA, Allander E, Elffors L, Dequeker J et al. Risk factors for hip fracture in European women: the MEDOS Study. Mediterranean Osteoporosis Study. J Bone Miner Res 1995;10:1802-15.

Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-6.

Yuan Z, Dawson N, Cooper GS, Einstadter D, Cebul R, Rimm AA. Effects of alcohol-related disease on hip fracture and mortality: a retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 2001;91:1089-93.

Lindholm J, Steiniche T, Rasmussen E, Thamsborg G, Nielsen IO, Brockstedt-Rasmussen H et al. Bone disorder in men with chronic alcoholism: a reversible disease? J Clin Endocrinol Metab 1991;73:118-24.

Vestergaard P, Hermann AP, Gram J, Jensen LB, Kolthoff N, Abrahamsen B et al. Improving compliance with hormonal replacement therapy in primary osteoporosis prevention. Maturitas 1997;28:137-45.

Christiansen C, Christensen MS, Transbol I. Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1981;1:459-61.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.

Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord 2001;2:7.

Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 2001;285:2891-7.

Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.

Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002;9:6-15.

Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96.

Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2001;285:1460-5.

Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R et al. Reproductive and hormonal factors and ovarian cancer. Ann Oncol 2001;12:337-41.

Norman RJ, Fleight IH, Ress, MC. Oestrogen and progesteron hormone replacement therapy for peri-menopausal and postmenopausal women: weight and body fat distribution. Cochrane Database Syst Rev2: CD001018-CD001018, 2000.

Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE et al. Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1995;332:767-73.

Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43.

Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.

Cummings SR, Black DM, Thompson DE, Applegate WB, BarrettConnor E, Musliner TA et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-10.

Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45.

Evista (Raloxifene HCL), product monograph. Eli Lilly Danmark AS, 2002.

Compston J, Watts N. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol (Oxf) 2002;56:565-9.

Christensen PM, Kristiansen IS, Brøsen K, Brixen KT, Abrahamsen B Andersen M. The use of prednisolon and concurrent pharmacological prophylaxis against osteoporosis - A population based study using a drug prescription database. J Bone Miner Res 14 (suppl 1), SU 369. 1999.

Mosekilde L. Rationel Farmakoterapi Osteoporose. Institut for Rationel Farmakoterapi, Lægemiddelstyrelsen, 2001.

Krølner B, Jørgensen PH. Lægemidler som forebyggelse. Hvordan bliver vi informeret og hvordan vejleder vi patienterne. Rationel Farmakoterapi 2002;3.

Kannus P, Parkkari J, Niemi S, Pasanen M, Palvanen M, Jarvinen M et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000;343:1506-13.

Chapuy MC, Arlot ME, Delmas PD, Meunier PJ. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2.

Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-42.